August 31, 2020 – Halifax, Nova Scotia – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”), a developer of rapid, point-of-care diagnostic tests, announced today it has engaged Bonham/Wills & Associates (“Bonham/Wills”), a leading sports consulting firm, to assist
August 25, 2020 – Halifax, Canada – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company”), a developer of rapid, point-of-care diagnostic tests, is pleased to announce that its rapid detection COVID-19 antigen test achieved a sensitivity of 84.6% and
Halifax, Nova Scotia–(Newsfile Corp. – August 6, 2020) – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company”), a developer of rapid, point-of-care diagnostic tests, announces that its previously announced clinical, in-field evaluation studies for its rapid detection, COVID-19 antigen
Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (“Sona Nanotech” or the “Company”), a developer of rapid, point-of-care diagnostic tests for COVID-19 and other applications, has engaged Maxim Group, LLC (“Maxim”) for general financial advisory and investment banking services in relation
July 2, 2020 – Halifax, Canada – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company”), a developer of rapid, point-of-care diagnostic tests, is pleased to announce that its rapid detection, COVID-19 antigen test’s laboratory validation studies of performance levels
Sona Nanotech Inc. is proud to be a participant of the Coronavirus Virtual Webinar Series, an online-only event occurring on June 17, 2020. A novel coronavirus emerged in China in late 2019; it has been officially named by the World Health
Sona Nanotech Comments on Trading Activity at Request of IIROC June 1, 2020 – Halifax, Canada – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company”) has been requested by the Investment Industry Regulatory Organization of Canada (IIROC) to comment
Sona Nanotech Engages MRIGlobal for COVID-19 Test Validation Studies May 22, 2020 – Halifax, Canada – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company”) is pleased to announce the engagement of MRIGlobal, a leading applied scientific research organization, to
May 12, 2020 – Halifax, Canada – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company”) is pleased to provide the following update on the development of its rapid-response, Covid-19 antigen test. The Company received confirmation from an independent laboratory
April 13, 2020 – Halifax, Canada – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company”) is pleased to provide an update on the development, manufacturing arrangements and pre-orders for its Covid-19 antigen test. The Company this past week has:
March 31, 2020 – Halifax, Canada – Sona Nanotech Inc. (CSE: SONA), (OTC Pink: SNANF) (the “Company”) is pleased to announce that it has been awarded a $4.1 million grant from NGen, Canada’s Advanced Manufacturing Supercluster, to develop and commercialize
March 30, 2020 – Halifax, Canada – Sona Nanotech Inc. (CSE: SONA), (OTC Pink: SNANF) (the “Company”) entered into service and supply agreements with a contract manufacturing organization (CMO) in Europe for the manufacture of its Covid-19 virus-detecting, rapid-response test.
SONA NANOTECH OBTAINS NEW OTC TRADING SYMBOL March 20, 2020 – Halifax, Canada – Sona Nanotech Inc. (CSE: SONA, OTC Pink: SNANF) (the “Company”) is pleased to announce that it has undertaken to further develop the U.S. trading market for
Halifax, Nova Scotia, March 19, 2020 – Sona Nanotech Inc. (“Sona”) (CSE: SONA) (OTC: LMTCF) is pleased to provide an update on the development of its rapid-response Covid-19 test. Sona is leading a consortium of diagnostic test developers including GE
March 17, 2020 – Halifax, Canada – Sona Nanotech Inc. (CSE: SONA) (the “Company”) is pleased to announce that it has granted 1,100,000 incentive stock options under the Company’s Stock Option Plan (“Option Plan”) of which 550,000 have been granted
Halifax, Nova Scotia, March 12, 2020 – Sona Nanotech Inc. (“Sona”) (CSE: SONA) (OTC: LMTCF) is pleased to provide a corporate update on recent activities. In the past several weeks, Sona has been focused on work related to the development
Halifax, Nova Scotia, March. 6, 2020 – Sona Nanotech Inc. (“Sona”) (CSE: SONA)(OTC:LMTCF) is pleased to provide an update on its Covid-19 rapid screening test as well as announcing the addition of Fiona Marshall and Sandy Morrison as scientific advisors
Halifax, Nova Scotia, March 3, 2020 – Sona Nanotech Inc. (“Sona”) (CSE: SONA) and GE Healthcare Life Sciences will jointly complete test development of the Sona Covid-19 Coronavirus rapid response lateral flow test, and will use GE Healthcare Life Sciences’
Halifax, Nova Scotia, February 18, 2020 – Sona Nanotech Inc. (CSE: SONA) has announced a partnership with UK-based medical technology company Bond Digital Health (Bond) to add data capture and analysis to its coronavirus (Covid-19) rapid screening test currently in
Halifax, Nova Scotia, Feb. 13, 2020 – Sona Nanotech Inc. (“Sona”) (CSE: SONA) has secured an agreement with The Native Antigen Company (“Native”) to supply biologics for the recently announced Covid-19 Coronavirus rapid screening test, currently in development by Sona
HALIFAX, Feb 10, 2020 — Sona Nanotech Inc. (“Sona”) (CSE: SONA) is deploying its proprietary nanotechnology in the development of a rapid screening test for the current Coronavirus, “nCoV19”. Sona is developing a quick-response lateral-flow test to screen patients
